Development, In-Vitro, Radiology and Research

News from AACR 2024: Sunday’s highlights

Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo

In-Vivo In-Vitro Antibody Protein

Vir awarded $1 billion multi-year BARDA influenza contract

pharmaphorum

OCTOBER 5, 2022

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55 million for rapid development of VIR-2482, the Vir Biotechnology’s investigational prophylactic monoclonal antibody (mAb) for seasonal and pandemic influenza viruses.

Antibody

Antibody In-Vitro Radiology Development

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial. Christoph D.

Antibody

Antibody In-Vivo Vaccination Vaccine

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

The Pharma Data

MARCH 25, 2022

” Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: “Today’s positive CHMP recommendation represents a significant step forward in our ongoing efforts to introduce additional, important preventative measures for people in Europe at higher risk of developing COVID-19. .”

Antibody

Antibody In-Vivo Medicine Vaccination

Top 10 Medical Device Companies in 2023 by Revenue Statistics and Trends

XTalks

JUNE 12, 2023

These powerhouse organizations have not only distinguished themselves through their cutting-edge devices and technologies but also via their robust research and development (R&D) capabilities, unwavering commitment to quality and extensive global reach. 1) Medtronic 2022 Revenue: Medtronic reported an annual revenue of $31.69

FDA Approval

FDA Approval Production Sales In-Vitro

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19

The Pharma Data

OCTOBER 22, 2020

The speed and rigor with which Veklury has been developed and approved in the U.S. Previously authorized by the FDA for emergency use to treat COVID-19, Veklury is now the first and only approved COVID-19 treatment in the United States.

FDA Approval

FDA Approval Trials Clinical Trials Clinical Trials

The Utility of Liquid Biopsy in Oncology Clinical Trials

XTalks

NOVEMBER 7, 2022

Liquid biopsies have demonstrated promising activity in multiple clinical settings, but the great enthusiasm and expectations around them can be harmful if not adequately managed,” said Dr. El Mustapha Bahassi, PhD, Director, Clinical Laboratory Sciences, at the global clinical research organization (CRO) Medpace.

Clinical Trials

Clinical Trials Clinical Trials Trials FDA Approval

A Final LDT Rule in April!? Will FDA be prepared?

FDA Law Blog

DECEMBER 11, 2023

Mullen — With comments due on the proposed LDT rule last week, FDA wasted no time updating the Unified Agenda to indicate that a final rule may be published in April ( here ). We take this date with a grain of salt given the frequency with which these dates are missed and given the volume of comments filed. (It

In-Vitro

In-Vitro Regulation Production Development

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

And in truth, the companies the White House picked were pretty savvy as several are current front-runners in the race to develop a vaccine. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine.

Vaccination

Vaccination Vaccine Antibody Life Science

New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention

The Pharma Data

NOVEMBER 18, 2021

In an analysis of the ongoing PROVENT trial assessing a median six months of party follow-up, one 300 mg IM cure of AZD7442 reduced the threat of developing characteristic COVID-19 compared to placebo by 83. About 2 of the global population is considered at increased threat of an shy response to a COVID-19 vaccine.1

Trials

Trials Antibody In-Vitro Vaccination

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

The Pharma Data

JUNE 25, 2021

In the overall trial population, AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% (95% confidence interval (CI): -26, 65) compared to placebo, which was not statistically significant (Table 1). The trial did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 compared to placebo.

Trials

Trials Antibody In-Vitro Medicine

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

The Pharma Data

AUGUST 22, 2021

Preliminary ‘in vitro’ findings from investigators at Oxford University and Columbia University demonstrate that AZD7442 neutralises recent emergent SARS-CoV-2 viral variants, including the Delta variant.(1-6). In the placebo arm, there were three cases of severe COVID-19, which included two deaths. About PROVENT.

Trials

Trials Antibody Vaccination Vaccine

AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US

The Pharma Data

OCTOBER 6, 2021

It’s the first LAAB with Phase III data demonstrating a statistically significant reduction in the threat of developing proper COVID-19 compared to placebo. In the Phase III PROVENT trial, AZD7442 reduced the peril of developing distinguishing COVID-19 by 77, compared to placebo. AZD7442 was well- let.

Antibody

Antibody In-Vitro Trials Vaccination

Clinical Research Informer

News from AACR 2024: Sunday’s highlights

Vir awarded $1 billion multi-year BARDA influenza contract

Trending Sources

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19

Top 10 Medical Device Companies in 2023 by Revenue Statistics and Trends

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19

The Utility of Liquid Biopsy in Oncology Clinical Trials

A Final LDT Rule in April!? Will FDA be prepared?

COVID-19 Pandemic Coverage

New analyses of two AZD7442 COVID-19 Phase III trials in high-risk populations confirm robust efficacy and long-term prevention

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US

Stay Connected